News

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS

NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for …

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS Read More »

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatments. NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human …

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases Read More »

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction

Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a …

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction Read More »

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members

New board members bring a wealth of financial, strategy and global health expertise.   NORTH BRUNSWICK, N.J., February 17, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the appointment of Dr. Kerry Maguire and Kris …

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members Read More »

January 2022: BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022

NORTH BRUNSWICK, N.J., January 24, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, reports highlights from its recent shareholder meeting. Highlights Include:  Clinical: Completed second clinical study in the EU and planning US phase 2/3 program …

January 2022: BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022 Read More »

October 2021: BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

NORTH BRUNSWICK, N.J., October 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announces that it was selected to present at the MACRO Trends Investor Conference on November 12, 2021. Co-founders Valerie Ceva, COO, and …

October 2021: BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium Read More »

September 2021: Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response

This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype.  NORTH BRUNSWICK, N.J., September 28, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown …

September 2021: Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response Read More »

August 2021: BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., August 27, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a case study, Recombinant Human Plasma Gelsolin (rhu-pGSN) in a Patient Hospitalized …

August 2021: BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient Read More »

June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection

NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced that it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant …

June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection Read More »

June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist

This distinguished awards program celebrates the unstoppable entrepreneurs whose unbounded ambitions deliver innovation, growth and prosperity that transform our world.   NORTH BRUNSWICK, N.J., June 4, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announces …

June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist Read More »